Minnesota Senate Bill 164, introduced on January 21, 2025, aims to enhance safety on college campuses by requiring public postsecondary institutions to maintain a supply of opiate antagonists, specifically nasal naloxone, to combat potential opioid overdoses. The bill mandates that each campus site must have at least two doses of naloxone readily available in campus buildings, with the Minnesota State Colleges and Universities Board of Trustees responsible for implementation. The University of Minnesota's Board of Regents is also requested to comply with the new regulations.

The legislation addresses the growing concern over opioid misuse and overdose, particularly among young adults. By ensuring that campuses are equipped with life-saving medication, the bill seeks to provide immediate assistance in emergency situations. Additionally, the Minnesota Department of Health will support institutions by providing training resources, including instructional videos, to facilitate effective emergency responses.

Debate surrounding the bill has focused on its potential impact on campus safety and the responsibilities of educational institutions. Proponents argue that the availability of naloxone could save lives and reduce the stigma associated with opioid use, while opponents raise concerns about the costs associated with maintaining supplies and training staff.

The bill is set to take effect in the 2025-2026 academic year, marking a significant step in Minnesota's efforts to address the opioid crisis within educational settings. As the legislation progresses, its implications for student health and safety, as well as the broader societal response to opioid addiction, will be closely monitored.